Design of effective immunotherapy for human autoimmunity

Nature

Volumn 435, Issue 7042, 2005, Pages 612-619

  Feldmann, Marc ^a   Steinman, Lawrence ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELLS; DISEASES; DRUG THERAPY; HUMAN ENGINEERING; TUMORS;

AUTOIMMUNE DISEASES; CYTOKINES; HUMAN DISEASES; IMMUNE DISORDERS;

IMMUNOLOGY;

ADALIMUMAB; ALPHA4 INTEGRIN; ALTERED PEPTIDE LIGAND; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA1 INTEGRIN; BETA1A INTERFERON; CD20 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA VACCINE; ETANERCEPT; GAMMA INTERFERON; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 60; HIGH MOBILITY GROUP B1 PROTEIN; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN; NATALIZUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RECOMBINANT INTERFERON; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTIGEN;

MEDICINE;

ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANKYLOSING SPONDYLITIS; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER RISK; CHRONIC DISEASE; CROHN DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOTHERAPY; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; LYMPHOMA; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIATIC ARTHRITIS; RELAPSE; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT OUTCOME; IMMUNOLOGY; LYMPHOCYTE; METHODOLOGY; PATHOLOGY;

ANIMALIA;

ANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES;

EID: 20444489218     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03727     Document Type: Review

References (80)

1. Sayegh, M. H. & Carpenter, C. B. Transplantation 50 years later - progress, challenges, and promises. N. Engl. J. Med. 351, 2761-2766 (2004).
2. Roep, B. O., Atkinson, M. & von Herrath, M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nature Rev. Immunol. 4, 989-997 (2004).
3. Bach, J. F. Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases. Arthritis Res. 4 (suppl. 3), S3-S15 (2002).
4. Malfait, A. M., Williams, R. O., Malik, A. S., Maini, R. N. & Feldmann, M. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44, 1215-1224 (2001).
5. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev. Immunol. 2, 364-371 (2002).
6. Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
7. Gladwell, M. The Tipping Point: How Little Things Can Make a Difference (Little, Brown & Co., Boston, 2000).
8. Feldmann, M. & Maini, R. N. Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Med. 9, 1245-1250 (2003).
9. Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4 β1 integrin. Nature 356, 63-66 (1992).
10. Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
11. Steinman, L. Immune therapy for autoimmune diseases. Science 305, 212-216 (2004).
12. Breedveld, F. C. Monoclonal antibodies to CD4. Rheum. Dis. Clin. North Am. 24, 567-578 (1998).
13. Lindsey, J. W. et al. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36, 183-189 (1994).
14. Chatenoud, L. CD8-specific antibody-induced active tolerance: from bench to bedside. Nature Rev. Immunol. 3, 123-132 (2003).
15. Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
16. Charpentier, B. et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 54, 997-1002 (1992).
17. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
18. Bottazzo, G. F., Pujol-Borrell, R., Hanafusa, T. & Feldmann, M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2, 1115-1119 (1983).
19. McDevitt, H. O., Perry, R. & Steinman, L. A. Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease. Ciba Found. Symp. 129, 184-193 (1987).
20. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
21. Humphreys, I. R. et al. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198, 1237-1242 (2003).
22. Shevach, E. M. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 50, 2721-2724 (2004).
23. + antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. USA 101 (suppl. 2), 14622-14626 (2004).
24. Kazkaz, H. & Isenberg, D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr. Opin. Pharmacol. 4, 398-402 (2004).
25. Oppenheim, J. J. & Feldmann, M. in Cytokine Reference, Vol. 1: Ligands (eds Oppenheim, J. J. & Feldmann, M.) 3-20 (Academic, London, 2001).
26. Feldmann, M. & Brennan, F. M. in Cytokine Reference, Vol. 1: Ligands (eds Oppenheim, J. J. & Feldmann, M.) 35-41 (Academic, London, 2001).
27. Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440 (1996).
28. Elliott, M. J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681-1690 (1993).
29. Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
30. Keystone, E. C. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400-1411 (2004).
31. Moreland, L. W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
32. Feldmann, M. & Maini, R. N. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
33. Nishimoto, N. & Kishimoto, T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 4, 386-391 (2004).
34. Butler, D. M., Maini, R. N., Feldmann, M. & Brennan, F. M. Modulation of proinflammatory cytoklne release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytakine Netw. 6, 225-230 (1995).
35. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998).
36. McInnes, I. B. & Gracie, J. A. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 4, 392-397 (2004).
37. Czura, C. J., Yang, H., Amelia, C. A. & Tracey, K. J. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv. Immunol. 84, 181-200 (2004).
38. Bekker, P. J. et al. A single-dose placebo-controlled study of AMG162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004).
39. Baggiolini, M. Reflections on chemokines. Immunol. Rev. 177, 5-7 (2000).
40. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314 (1994).
41. Yu, M., Johnson, J. M. & Tuohy, V. K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183, 1777-1788 (1996).
42. Sela, M. The concept of specific immune treatment against autoimmune diseases. Int. Rev. Immunol. 18, 201-216 (1999).
43. Brocke, S. et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379, 343-346 (1996).
44. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group. Nature Med. 6, 1176-1182 (2000).
45. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167-1175 (2000).
46. Ruiz, P. J. et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell co-stimulation. J. Immunol. 162, 3336-3341 (1999).
47. Raz, I. et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001).
48. Robinson, W. H. et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nature Biotechnol. 21, 1033-1039 (2003).
49. Gutgemann, I., Fahrer, A. M., Altman, J. D., Davis, M. M. & Chien, Y. H. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. Immunity 8, 667-673 (1998).
50. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. & Weiner, H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
51. Toussirot, E. A. Oral tolerance in the treatment of rheumatoid arthritis. Curr. Drug Targets Inflamm. Allergy 1, 45-52 (2002).
52. Knight, D. M. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443-1453 (1993).
53. Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 (1994).
54. Chiller, J. M., Habicht, G. S. & Weigle, W. O. Cellular sites of immunologic unresponsiveness. Proc. Natl Acad. Sci. USA 65, 551-556 (1970).
55. Bathon, J. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
56. Walmsley, M. et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 39, 495-503 (1996).
57. Adams, G., Vessillier, S., Dreja, H. & Chernajovsky, Y. Targeting cytokines to inflammation sites. Nature Biotechnol. 21, 1314-1320 (2003).
58. Steinman, L. Engineering better cytokines. Nature Biotechnol. 21, 1293-1294 (2003).
59. Revel, M. Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol. Ther. 100, 49-62 (2003).
60. Steed, P. M. et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301, 1895-1898 (2003).
61. Quinn, M. A. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 27-35 (2005).
62. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594-1602 (2000).
63. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
64. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
65. Day, R. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 359, 540-541 (2002).
66. Pisetsky, D. S. & St Clair, E. W. Progress in the treatment of rheumatoid arthritis. JAMA 286, 2787-2790 (2001).
67. Brennan, F. M. et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells. Arthritis Rheum. 46, 31-41 (2002).
68. Charles, P. J., Smeenk, R. J. T., DeJong, J., Feldmann, M. & Maini, R. N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum. 43, 2383-2390 (2000).
69. Baecklund, E., Askling, J., Rosenquist, R., Ekbom, A. & Klareskog, L. Rheumatoid arthritis and malignant lymphomas. Curr. Opin. Rheumatol. 16, 254-261 (2004).
70. Cope, A. P. et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94, 749-760 (1994).
71. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
72. Vollmer, T. et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608 (2004).
73. Kwak, B., Mulhaupt, F., Myit, S, & Mach, F. Statins as a newly recognized type of immunomodulator. Nature Med. 6, 1399-1402 (2000).
74. Garren, H. et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15-22 (2001).
75. Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
76. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
77. Lovett-Racke, A. E. et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172, 5790-5798 (2004).
78. Dalbeth, N., Edwards, J., Fairchild, S., Callan, M. & Hall, F. C. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 44, 24-31 (2005).
79. Williams, R. O., Mason, L. J., Feldmann, M. & Maini, R. N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl Acad. Sci. USA 91, 2762-2766 (1994).
80. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412-1419 (2004).